2020-2027 Analysis and Review Sivelestat Sodium Market

Sivelestat Sodium Market

Sivelestat Sodium Market By Treatment (Acute Lung Injury, Pediatric Cardiopulmonary Bypass Surgery and Others), By End Users (Hospital & Clinics, Ambulatory Surgical Centers and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027

08-04-2020 REP-HC-5062 40 Tables 120 pages Format

The sivelestat sodium market was valued at USD80.4Mn by 2019. The rising prevalence of acute lung failure worldwide primarily drives the sivelestat sodium market growth. Recently the National Medical Products Administration of China (NMPA), has given approval for the use of sivelestat sodium in the treatment of COVID-19 infection, this serves important research findings that will motivate global pharmaceutical companies to produce sivelestat sodium drug formulation for curbing the mortality rate associated with COVID-19 infection.

 Sivelestat Sodium Market

Sivelestat sodium was developed by Ono Pharmaceutical Co., Ltd. as a competitive inhibitor of neutrophil elastase which is employed for the treatment of acute lung injury related to systemic inflammatory response syndrome.

The major segments related to the sivelestat sodium market are:

By Treatment (2017–2027; US$ Mn)

Acute Lung Injury

Pediatric Cardiopulmonary Bypass Surgery

Others

By End Users (2017–2027; US$ Mn)

Hospital & Clinics

Ambulatory Surgical Centers

Others

Geography Segment(2017–2027; US$ Mn)

North America

United States
Canada

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA

Justification for study?

  • The intention of the study is to give a comprehensive outlook of the global sivelestat sodium market
  • The overall segmentation of the sivelestat sodium market, by treatment, end-users, and geography is minutely studied. Acute lung injury and hospital & clinics are dominating the treatment and end-users segments respectively
  • Constant rise in acute lung failure worldwide
  • Promising results obtained in clinical trials studies pertaining to the treatment of acute respiratory distress syndrome (ARDS) associated with COVID-19 infection

Report gist?

  • The study of the global sivelestat sodium market includes qualitative analysis of factors such as drivers, restraints, and opportunities
  • The report covers qualitative and quantitative analysis of the overall market segmented on the basis of treatment and end-users and categorization of the same at geography level
  • This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. Compounded annual growth rate is calculated for the respective segments from 2020 to 2027
  • The study includes the profiles of major market players with a significant global and regional presence along with top company positioning

Significant customers?

  • This study is suitable for industry participants and stakeholders in the pharmaceutical companies engaged in the production of sivelestat sodium for the treatment of acute lung injury
  • The report will benefit researchers engaged in the clinical trial studies pertaining to therapeutic efficacy and safety of sivelestat sodium in the treatment of ARDS related to COVID-19 infection
  • Managers with financial institutions looking to publish recent and forecasted statistics pertaining to sivelestat sodium market
  • Financial institutions venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies 

Segment Analysis

Acute lung injury is currently dominating the treatment segment for the sivelestat sodium market. The most common risk factors associated with acute respiratory distress syndrome is an aspiration, pneumonia, and extrapulmonary sepsis, etc. It is basically an inflammatory process that is associated with refractory hypoxemia, accumulation of pulmonary edema which increases the stiffness of the lungs and renders them incapable of eliminating carbon dioxide. It is still the most undertreated medical condition which has a mortality rate of 40%. Pediatric cardiopulmonary bypass surgery is estimated to be registering rampant market growth in the near future on account of the ability of sivelestat sodium in reducing the perioperative inflammatory response and drastically reduces the duration of mechanical ventilation.

Hospitals and clinics are leading the end-user segment for the sivelestat sodium market. It is the first point of contact for patients to be hospitalized in critical care units for the treatment of acute lung injury. Mechanical ventilation is the most widely employed treatment option for treating acute lung injury which is installed and functioning in the government-funded hospitals worldwide. Ambulatory surgical centers are gaining strong grounds on account of its ability to serve patients residing in remote locations and provisions of life-saving medicines and mechanical ventilators for stabilizing patients with respiratory complications.

Asia Pacific is currently representing the largest market share in the geography segment for the sivelestat sodium market. Rising prevalence of acute respiratory distress syndrome (ARDS), primarily drives its market growth. As per the research findings provided by the World Health Organization (WHO), the annual incidence rate of acute respiratory distress syndrome in the Asia Pacific region is 15.19 per 100,000 people. Additionally the developing healthcare infrastructure and domicile of key players such as Ono Pharmaceutical Co., Ltd, Teva Takeda Yakuhin Ltd, and Shanghai Huilun Jiangsu Pharmaceutical Co. Ltd, etc. consolidates the market growth in the region. Europe is placed in the second position owing to the rising prevalence of sepsis-induced acute lung injury across all age groups. The high mortality rate associated with COVID -19 induced acute respiratory failure has resulted in the implementation of clinical trial studies to treat the therapeutic efficacy and safety of sivelestat sodium in its treatment in the European Union region. North America is anticipated to be the fastest-growing regional segment during the forecast period on account of the rising prevalence of acute lung failure. According to the recent facts provided by the American Journal of Respiratory and Critical Care Medicine annually in the United States 74,500 people die due to acute lung injury.

Select License Type

$4,600
$6,600
$9,500

Safe and Secure SSL Encrypted

Have a Question?

We will help you find what you are looking for.

Call 1-518-730-1560

Contact sales

How can we help you?

Get in touch with us or find an office closest to you.